This study was designed to demonstrate that dopaminergic stimulation would result in decreased smoking behavior and nicotine intake, whereas dopaminergic blockade would result in increased smoking behavior and nicotine intake, in the same subjects. In prior human studies, a dopaminergic antagonist, haloperidol, increased smoking and/or nicotine intake, and a dopamine agonist, bromocriptine, dec...

Bromocriptine (2-bromo-a-ergocryptine) inhibited prolactin release when added to primary cultures of dispersed pituitary glands from male rats. The total amount of prolactin (intracellular plus extracellular) was reduced to less than 20% of control values after 6 days. The amount of intracellular prolactin was increased in treated cultures and the total amount of hormone was the same in control...

The metabolic syndrome comprises a cluster of metabolic anomalies including insulin resistance, abdominal obesity, dyslipidemia, and hypertension. Previous studies suggest that impaired dopamine D2 receptor (D2R) signaling is involved in its pathogenesis. We studied the acute effects of bromocriptine (a D2R agonist) on energy metabolism in obese women; body weight and caloric intake remained co...

In order to study the mode of action of TRH and sulpiride in man, we administered TRH (500 micrograms, iv) and sulpiride (DA D2 receptor antagonist, 100 mg, im) simultaneously to 6 normal females (20-21 yr). Normal females showed significantly greater PRL increments and AUC in response to the combined administration compared to a single administration of each agent (P < 0.05-0.01), while the in...

Sixty-three patients with Parkinson's disease who failed bromocriptine therapy for various reasons were treated in an open-label trial of pergolide. The data were evaluated in a retrospective manner. Forty-six percent had a good response and tolerated the pergolide. A comparison of the outcomes regarding response and toxicity revealed that bromocriptine and pergolide act differently in individu...

Prolactin-secreting pituitary tumors are now recognized as a common endocrinologic problem [1]. Bromocriptine is an ergot alkaloid which, by virtue of its agonist action at the dopamine receptor, is effective in lowering serum prolactin levels [2). Although a number of reports have shown reduction in tumor size with bromocriptine therapy [3-8], documentation of rapid regression of tumor size is...

background patients with intellectual disabilities may be treated with antipsychotic medications for a variety of diagnoses. use of this category of medication can increase prolactin levels and place the patient at risk for sexual dysfunction and lower bone mineral density. the proposed mechanism of action is affinity for the dopamine receptor. use of bromocriptine, a dopamine receptor antagoni...

Background: As previous studies show, several effects of morphine are induced by the dopaminergic system. Sulpiride is a dopamine D2 receptor (DAD2) antagonist widely used in clinics to treat DArelated disorders. DAD2 receptors are abundant at hippocampal cornu ammonis (CA1). Objectives: This study aimed to investigate the possible interaction of morphine and sulpiride on DA synapses in CA1...